Alnylam cuts 2026 sales forecast, stock plunges over 28% after weak Q2 results

Alnylam Pharmaceuticals lowered its full-year 2026 sales guidance by about $200 million due to slower-than-expected growth in its TTR product after initial launch demand normalized. This announcement followed the company’s disappointing second quarter financial results released on July 30, 2026. As a result, Alnylam's stock price dropped more than 28%, causing significant losses for investors. A law firm is investigating potential securities law violations and is inviting affected investors to discuss their legal rights.